Targeted Therapies for Previously “Undruggable” KRAS-Mutated Non–Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib

Abstract

Objective:

To evaluate the safety and efficacy of the novel KRAS-targeting agents, sotorasib and adagrasib, in treating KRAS G12C-mutated non–small cell lung cancer (NSCLC).

Data Sources:

A comprehensive English-based literature search of PubMed and Clinicaltrials.gov between January 2000 and July 2023 was conducted using the terms sotorasib, Lumakras, AMG 510, adagrasib, Krazati, and MRTX849.

Study Selection and Data Extraction:

Relevant prescribing information, clinical trials, and treatment guidelines were evaluated.

Data Synthesis:

Sotorasib and adagrasib received accelerated US Food and Drug Administration (FDA) approval following pivotal phase I/II clinical trials. Sotorasib, a first-in-class KRAS inhibitor, demonstrated an overall response rate (ORR) of 41% and a progression-free survival (PFS) of 6.3 months. In a phase III confirmatory trial, sotorasib showed significantly longer PFS compared with docetaxel (5.6 vs. 4.5 months; P = 0.0017). Adagrasib produced an ORR of 42.9% and a PFS of 6.5 months. Both drugs present unique safety profiles, with common toxicities, including diarrhea, musculoskeletal pain, fatigue, and hepatotoxicity.

Relevance to Patient Care and Clinical Practice:

With KRAS mutations being among the most common oncogenic alterations in NSCLC, sotorasib and adagrasib offer new therapeutic avenues for this previously “undruggable” target. Current treatment guidelines list sotorasib and adagrasib as second-line options in patients with confirmed KRAS G12C-mutated NSCLC. Additional studies are required to further differentiate the safety and efficacy profiles of these 2 agents and identify their optimal place in therapy.

Conclusion:

Sotorasib and adagrasib demonstrated promising outcomes in targeting the constitutively active KRAS G12C oncogenic driver, underscoring the need for further research to optimize their therapeutic application in this high-risk population.

Keywords

KRAS inhibitor non–small cell lung cancer small molecule inhibitor sotorasib adagrasib krazati lumakras

Get full access to this article

View all access options for this article.

References

Sung

Ferlay

Siegel

, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

World Cancer Research Fund International. Lung cancer statistics. Accessed August 9, 2023. https://www.wcrf.org/cancer-trends/lung-cancer-statistics/

Zappa

Mousa

SA.

Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288-300. doi:10.21037/tlcr.2016.06.07

American Cancer Society. Cancer facts and figures 2023. Published 2023. Accessed August 9, 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf

Yanagawa

Riely

GJ.

Management of patients with resectable and metastatic non–small cell lung cancer. J Natl Compr Canc Netw. 2022;20(5.5):1-5. doi:10.6004/jnccn.2022.5022

Cohen

Johnson

Chen

Sridhara

Pazdur

FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10(7):461-466. doi:10.1634/theoncologist.10-7-461

Kristina Gregory

Miranda Hughes

Aisner

, et al. NCCN guidelines version 3.2023 Non-small cell lung cancer. Published April 2023. Accessed August 7, 2023. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

Hofmann

Gerlach

Misale

Petronczki

Kraut

Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 2022;12(4):924-937. doi:10.1158/2159-8290.CD-21-1331

Karimi

Moghaddam

SJ.

KRAS-mutant lung cancer: targeting molecular and immunologic pathways, therapeutic advantages and restrictions. Cells. 2023;12(5):749. doi:10.3390/cells12050749

10.

Hobbs

Der

Rossman

KL.

RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129(7):1287-1292. doi:10.1242/jcs.182873

11.

Singh

Longo

Chabner

BA.

Improving prospects for targeting RAS. J Clin Oncol. 2015;33(31):3650-3659. doi:10.1200/JCO.2015.62.1052

12.

Tomasini

Walia

Labbe

Jao

Leighl

NB.

Targeting the KRAS pathway in non-small cell lung cancer. Oncologist. 2016;21(12):1450-1460. doi:10.1634/theoncologist.2015-0084

13.

Lee

Tan

Zhou

, et al. Clinical characteristics and outcomes in advanced KRAS-Mutated NSCLC: a multicenter collaboration in Asia (ATORG-005). JTO Clin Res Rep. 2022;3(1):100261. doi:10.1016/j.jtocrr.2021.100261

14.

Cascetta

Marinello

Lazzari

, et al. KRAS in NSCLC: state of the art and future perspectives. Cancers (Basel). 2022;14(21):5430. doi:10.3390/cancers14215430

15.

Dogan

Shen

Ang

, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18:6169-6177. doi: 10.1158/1078-0432.CCR-11-3265

16.

Moore

Rosenberg

McCormick

Malek

RAS-targeted therapies: is the undruggable drugged?

Nat Rev Drug Discov. 2020;19(8):533-552. doi:10.1038/s41573-020-0068-6

17.

Skoulidis

Byers

Diao

, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5(8):860-877. doi:10.1158/2159-8290.CD-14-1236

18.

Ostrem

Peters

Sos

Wells

Shokat

KM.

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548-551. doi:10.1038/nature12796

19.

Nakajima

Drezner

, et al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res. 2022;28(8):1482-1486. doi:10.1158/1078-0432.CCR-21-3074

20.

US Food and Drug Administration. FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC. Accessed August 9, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc#:~:text=On%20December%2012%2C%202022%2C%20the,by%20an%20FDA%2Dapproved%20test%2C

21.

Lumakras (sotorasib) [package insert]. Amgen Inc. Published November, 2022. Accessed August 9, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214665s002lbl.pdf

22.

SHI

Jänne

Leal

, et al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1). J Clin Oncol. 2022;40(23):2530-2538. doi:10.1200/JCO.21.02752

23.

Hong

Fakih

Strickler

, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207-1217. doi:10.1056/NEJMoa1917239

24.

Skoulidis

, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371-2381. doi:10.1056/NEJMoa2103695

25.

Canon

Rex

Saiki

, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217-223. doi:10.1038/s41586-019-1694-1

26.

Jänne

Riely

Gadgeel

, et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387(2):120-131. doi:10.1056/NEJMoa2204619

27.

Hallin

Engstrom

Hargis

, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54-71. doi:10.1158/2159-8290.CD-19-1167

28.

Krazati (adagrasib) [package insert]. Mirati pharmaceutics. Published December, 2022. Accessed August 9, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf

29.

Fell

Fischer

Baer

, et al. Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer. J Med Chem. 2020;63(13):6679-6693. doi:10.1021/acs.jmedchem.9b02052

30.

Jänne

Papadopoulos

Rybkin

Johnson

. NASDAQ: MRTX targeting the genetic and immunological drivers of cancer. A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRAS G12C inhibitor, in advanced solid tumors. Paper presented at AACR-NCI-EORTC International Conference on Molecular Targets; October 28, 2019; Virtual meeting.

31.

Arbour

Jordan

Kim

, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin Cancer Res. 2018;24(2):334-340. doi:10.1158/1078-0432.CCR-17-1841

32.

Govindan

Velcheti

, et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100. J Clin Oncol. 2023;41(18):3311-3317. doi:10.1200/JCO.22.02524

33.

de Langen

Johnson

Mazieres

, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401(10378):733-746. doi:10.1016/S0140-6736(23)00221-0

34.

Arbour

Khurana

Dai

Skoulidis

. Trial in progress: a phase 2 study of sotorasib as first-line treatment in patients with stage IV non–small cell lung cancer (NSCLC) whose tumors harbor a KRAS p.G12C mutation (CodeBreaK 201). J Clin Oncol. 2022;40(suppl. 16):TPS9150-TPS9150. doi:10.1200/JCO.2022.40.16_suppl.TPS9150

35.

Thummalapalli

Bernstein

Herzberg

, et al. Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer. JCO Precis Oncol. 2023;7:e2300030. doi:10.1200/PO.23.00030

36.

Ettinger

Berger

Agarwal

, et al. NCCN guidelines version 2.2023 Antiemesis. Published May, 2023. Accessed August 8, 2023. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf

37.

Schoenfeld

Nishino

Severgnini

Manos

Mak

Hodi

FS.

Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunotherapy Cancer. 2019;7:112. doi:10.1186/s40425-019-0583-3

38.

Zhang

Johnson

Barve

, et al. Practical guidance for the management of adverse events in patients with KRASG12C-mutated non-small cell lung cancer receiving adagrasib. Oncologist. 2023;28(4):287-296. doi:10.1093/oncolo/oyad051

39.

O’Sullivan Keogh

ÉA

Henderson

Finn

Gray

Gately

Treatment Strategies for KRAS-mutated non-small-cell lung cancer. Cancers (Basel). 2023;15(6):1635. doi:10.3390/cancers15061635

40.

Burns

Borghaei

Ramalingam

Mok

Peters

Targeting KRAS-mutant non–small-cell lung cancer: one mutation at a time, with a focus on KRAS G12C mutations. J Clin Oncol. 2020;38(35):4208-4218. doi:10.1200/JCO.20.00744

41.

Neoadjuvant KRAS G12C directed therapy with adagrasib (MRTX849) with or without nivolumab (Neo-Kan). Accessed August 9, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT05472623

42.

Falchook

Durm

, et al. OA03.06 CodeBreaK 100/101: first report of safety/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC. J Thorac Oncol. 2022;17(9):S10-S11. doi:10.1016/j.jtho.2022.07.025

43.

Sabari

Velcheti

Shimizu

, et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer. Clin Cancer Res. 2022;28(15):3318-3328. doi:10.1158/1078-0432.CCR-22-0383

44.

Cui

Franchini

Alexander

, et al. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Lung Cancer. 2020;146:310-317. doi:10.1016/j.lungcan.2020.06.030

45.

Zhang

Strickland

, et al. Clinical and imaging features of non-small cell lung cancer with G12C KRAS mutation. Cancers (Basel). 2021;13(14):3572. doi:10.3390/cancers13143572

46.

Sebastian

Eberhardt

WEE

Hoffknecht

, et al. KRAS G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315). Lung Cancer. 2021;154:51-61. doi:10.1016/j.lungcan.2021.02.005

47.

IBM Corporation. IBM micromedex®. Accessed August 2, 2022. https://www.micromedexsolutions.com/home/dispatch?navitem=headerGateway